Tomas Thor Agustsson1, Tinna Baldvinsdottir2, Jon G Jonasson3, Elinborg Olafsdottir4, Valgerdur Steinthorsdottir2, Gunnar Sigurdsson2, Arni V Thorsson3, Paul V Carroll4, Márta Korbonits4, Rafn Benediktsson2. 1. The Department of Endocrinology and Metabolic MedicineLandspítali - The National University Hospital of Iceland. Fossvogur, 108 Reykjavík, IcelandThe Faculty of MedicineThe University of Iceland, Vatnsmýrarvegur 16, 101 Reykjavík, IcelandThe Department of PathologyLandspítali - The National University Hospital of Iceland, Fossvogur, 108 Reykjavík, IcelandThe Icelandic Cancer RegistrySkógarhlíð 8, 105 Reykjavík, IcelanddeCODE geneticsSturlugata 8, 101 Reykjavík, IcelandThe Paediatric DepartmentLandspitali - The National University Hospital of Iceland, Hringbraut, 101 Reykjavík, IcelandThe Department of Diabetes and EndocrinologyGuy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, UKEndocrinologyThe William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK The Department of Endocrinology and Metabolic MedicineLandspítali - The National University Hospital of Iceland. Fossvogur, 108 Reykjavík, IcelandThe Faculty of MedicineThe University of Iceland, Vatnsmýrarvegur 16, 101 Reykjavík, IcelandThe Department of PathologyLandspítali - The National University Hospital of Iceland, Fossvogur, 108 Reykjavík, IcelandThe Icelandic Cancer RegistrySkógarhlíð 8, 105 Reykjavík, IcelanddeCODE geneticsSturlugata 8, 101 Reykjavík, IcelandThe Paediatric DepartmentLandspitali - The National University Hospital of Iceland, Hringbraut, 101 Reykjavík, IcelandThe Department of Diabetes and EndocrinologyGuy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, UKEndocrinologyThe William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK tomasa@landspitali.is. 2. The Department of Endocrinology and Metabolic MedicineLandspítali - The National University Hospital of Iceland. Fossvogur, 108 Reykjavík, IcelandThe Faculty of MedicineThe University of Iceland, Vatnsmýrarvegur 16, 101 Reykjavík, IcelandThe Department of PathologyLandspítali - The National University Hospital of Iceland, Fossvogur, 108 Reykjavík, IcelandThe Icelandic Cancer RegistrySkógarhlíð 8, 105 Reykjavík, IcelanddeCODE geneticsSturlugata 8, 101 Reykjavík, IcelandThe Paediatric DepartmentLandspitali - The National University Hospital of Iceland, Hringbraut, 101 Reykjavík, IcelandThe Department of Diabetes and EndocrinologyGuy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, UKEndocrinologyThe William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK The Department of Endocrinology and Metabolic MedicineLandspítali - The National University Hospital of Iceland. Fossvogur, 108 Reykjavík, IcelandThe Faculty of MedicineThe University of Iceland, Vatnsmýrarvegur 16, 101 Reykjavík, IcelandThe Department of PathologyLandspítali - The National University Hospital of Iceland, Fossvogur, 108 Reykjavík, IcelandThe Icelandic Cancer RegistrySkógarhlíð 8, 105 Reykjavík, IcelanddeCODE geneticsSturlugata 8, 101 Reykjavík, IcelandThe Paediatric DepartmentLandspitali - The National University Hospital of Iceland, Hringbraut, 101 Reykjavík, IcelandThe Department of Diabetes and EndocrinologyGuy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, UKEndocrinologyThe William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK. 3. The Department of Endocrinology and Metabolic MedicineLandspítali - The National University Hospital of Iceland. Fossvogur, 108 Reykjavík, IcelandThe Faculty of MedicineThe University of Iceland, Vatnsmýrarvegur 16, 101 Reykjavík, IcelandThe Department of PathologyLandspítali - The National University Hospital of Iceland, Fossvogur, 108 Reykjavík, IcelandThe Icelandic Cancer RegistrySkógarhlíð 8, 105 Reykjavík, IcelanddeCODE geneticsSturlugata 8, 101 Reykjavík, IcelandThe Paediatric DepartmentLandspitali - The National University Hospital of Iceland, Hringbraut, 101 Reykjavík, IcelandThe Department of Diabetes and EndocrinologyGuy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, UKEndocrinologyThe William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK The Department of Endocrinology and Metabolic MedicineLandspítali - The National University Hospital of Iceland. Fossvogur, 108 Reykjavík, IcelandThe Faculty of MedicineThe University of Iceland, Vatnsmýrarvegur 16, 101 Reykjavík, IcelandThe Department of PathologyLandspítali - The National University Hospital of Iceland, Fossvogur, 108 Reykjavík, IcelandThe Icelandic Cancer RegistrySkógarhlíð 8, 105 Reykjavík, IcelanddeCODE geneticsSturlugata 8, 101 Reykjavík, IcelandThe Paediatric DepartmentLandspitali - The National University Hospital of Iceland, Hringbraut, 101 Reykjavík, IcelandThe Department of Diabetes and EndocrinologyGuy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, UKEndocrinologyThe William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK The Department of Endocrinology and Metabolic MedicineLandspítali - The National University Hospital of Iceland. Fossvogur, 108 Reykjavík, IcelandThe Faculty of MedicineThe University of Iceland, Vatnsmýrarvegur 16, 101 Reykjavík, Icela 4. The Department of Endocrinology and Metabolic MedicineLandspítali - The National University Hospital of Iceland. Fossvogur, 108 Reykjavík, IcelandThe Faculty of MedicineThe University of Iceland, Vatnsmýrarvegur 16, 101 Reykjavík, IcelandThe Department of PathologyLandspítali - The National University Hospital of Iceland, Fossvogur, 108 Reykjavík, IcelandThe Icelandic Cancer RegistrySkógarhlíð 8, 105 Reykjavík, IcelanddeCODE geneticsSturlugata 8, 101 Reykjavík, IcelandThe Paediatric DepartmentLandspitali - The National University Hospital of Iceland, Hringbraut, 101 Reykjavík, IcelandThe Department of Diabetes and EndocrinologyGuy's and St Thomas' NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, UKEndocrinologyThe William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK.
Abstract
OBJECTIVE: Pituitary adenomas (PA) are among the most common human neoplasms. To describe the epidemiology and assess the disease burden of clinically significant PAs, population-based studies are needed. Iceland has a small well-defined population. The aim of this study is to describe the epidemiology of PAs in Iceland over an expanded period of time. DESIGN: This is a retrospective observational study, including all PAs diagnosed in Iceland from 1955 to 2012. METHODS: Extensive clinical information was gathered in a database. Prevalence rates for all PA subtypes were calculated along with standardized incidence rates (SIR). Sex ratios and relationships with adenoma size, age, and symptoms were assessed. RESULTS: We identified 471 individuals: 190 men and 281 women. Total prevalence in 2012 was 115.57/100, 000, prolactinomas were most prevalent (54.37/100, 000) followed by non-functioning adenomas (NFPAs) (42.32/100 ,000). Throughout the period, NFPAs were most common (43.0%) followed by prolactinomas (39.9%) and 11.3% had acromegaly and 5.7% Cushing's disease. Women are diagnosed younger with smaller adenomas. Total SIR has increased significantly and is now 5.8/100 000 per year. CONCLUSION: In this nationwide study spanning six decades, we have confirmed PAs rising prevalence and incidence rates noted in recent studies. We demonstrated higher overall prevalence and incidence rates than ever previously recorded with an increasing predominance of NFPAs, which is not explained by incidental findings alone. There is a relationship with the introduction of imaging modalities, but the vast majority of patients are symptomatic at diagnosis. This underlines the importance of increased awareness, education, and appropriate allocation of resources for this growing group of patients.
OBJECTIVE:Pituitary adenomas (PA) are among the most common humanneoplasms. To describe the epidemiology and assess the disease burden of clinically significant PAs, population-based studies are needed. Iceland has a small well-defined population. The aim of this study is to describe the epidemiology of PAs in Iceland over an expanded period of time. DESIGN: This is a retrospective observational study, including all PAs diagnosed in Iceland from 1955 to 2012. METHODS: Extensive clinical information was gathered in a database. Prevalence rates for all PA subtypes were calculated along with standardized incidence rates (SIR). Sex ratios and relationships with adenoma size, age, and symptoms were assessed. RESULTS: We identified 471 individuals: 190 men and 281 women. Total prevalence in 2012 was 115.57/100, 000, prolactinomas were most prevalent (54.37/100, 000) followed by non-functioning adenomas (NFPAs) (42.32/100 ,000). Throughout the period, NFPAs were most common (43.0%) followed by prolactinomas (39.9%) and 11.3% had acromegaly and 5.7% Cushing's disease. Women are diagnosed younger with smaller adenomas. Total SIR has increased significantly and is now 5.8/100 000 per year. CONCLUSION: In this nationwide study spanning six decades, we have confirmed PAs rising prevalence and incidence rates noted in recent studies. We demonstrated higher overall prevalence and incidence rates than ever previously recorded with an increasing predominance of NFPAs, which is not explained by incidental findings alone. There is a relationship with the introduction of imaging modalities, but the vast majority of patients are symptomatic at diagnosis. This underlines the importance of increased awareness, education, and appropriate allocation of resources for this growing group of patients.
Authors: Haley Gittleman; David J Cote; Quinn T Ostrom; Carol Kruchko; Timothy R Smith; Elizabeth B Claus; Jill S Barnholtz-Sloan Journal: J Neurooncol Date: 2017-06-30 Impact factor: 4.130
Authors: Ken K Y Ho; Maria Fleseriu; John Wass; Aart van der Lely; Ariel Barkan; Andrea Giustina; Felipe F Casanueva; Anthony P Heaney; Nienke Biermasz; Christian Strasburger; Shlomo Melmed Journal: Pituitary Date: 2019-12 Impact factor: 4.107
Authors: Pietro Mortini; Gianluca Nocera; Francesca Roncelli; Marco Losa; Anna Maria Formenti; Andrea Giustina Journal: Rev Endocr Metab Disord Date: 2020-12 Impact factor: 6.514